Medical devices, healthcare technology and the business of care
PMA approval · P250031

VENTANA PTEN (SP218) RxDx Assay

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Decision date Jun 12, 2026

FDA DECISIONP250031

What did the FDA approve?

FDA records P250031 as an original PMA application. The recorded decision is approval, dated Jun 12, 2026.

FDA approval order statement

VENTANA PTEN (SP218) RxDx Assay is a qualitative immunohistochemical (IHC) assay using rabbit monoclonal anti-PTEN, clone SP218, intended for laboratory use in the assessment of phosphatase and tensin homolog (PTEN) protein in formalin-fixed paraffin-embedded (FFPE) prostatic adenocarcinoma tissue specimens by light microscopy. The assay is for use with OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument. The assay is indicated as a companion diagnostic to aid in identifying patients who may be eligible for treatment with TRUQAP (capivasertib) in combination with abiraterone acetate in accordance with the approved therapeutic product labeling. The clinical cutoff for PTEN Loss status is >=90% of viable malignant cells with no specific cytoplasmic staining.Test results should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.This product is intended for in vitro diagnostic (IVD) use.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Jun 12, 2026

FDA source record

Regulatory record facts

Identifier
P250031
Regulatory pathway
Premarket approval application
Product code
SHF
Decision code
APPR
Decision date
Jun 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry Assay, Antibody.

Product code
SHF

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250031 received

    Application receipt date recorded by FDA.

  2. P250031 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250031. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1910 E. Innovation Park Dr., Tucson, AZ, 85755

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records